Literature DB >> 23423465

A cohort study on myasthenia gravis patients in China.

Wei Wang1, Yu-Ping Chen, Zhong-Kui Wang, Dong-Ning Wei, Ling Yin.   

Abstract

Clinical classification and age distribution in myasthenia gravis (MG) cases seem different between Oriental and Caucasian populations, but there have rarely been any clinical studies on MG patients from mainland China. The goal of the current study was to perform a comprehensive survey of myasthenia gravis in a hospital in China, establishing contemporary cohort data and clinical features. 1,108 unselected patients with MG attending the 309th Hospital of PLA, Beijing, China were studied during a 36-month period from July 2008 to June 2011. The sex ratio was 1:1 (F:M). 62.5 % of patients presented as adolescents and adults. Ocular MG cases accounted for 65.6 % childhood MG patients. A positive response was observed in 96.8 % of the patients for neostigmine tests, whereas a positive decremental response to low frequency repetitive nerve stimulation (RNS) was observed in 77.4 % of the patients. The highest stimulating positive rate was 65.3 % in stimulated facial nerve. Thymoma was significantly increased in those patients with severe MG, especially in the cohort involving the respiratory muscles (p < 0.001). The study revealed higher frequency of ocular and childhood MG compared to other studies in USA and European countries, which can be a result of optimum case ascertainment, increased disease duration, or application of complex diagnostic tests. The relative increase in the prevalence of ocular myasthenia can be attributed to the impact of an aging population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23423465     DOI: 10.1007/s10072-013-1329-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  15 in total

1.  Myasthenia gravis: a higher than expected incidence in the elderly.

Authors:  J M Aragonès; I Bolíbar; X Bonfill; E Bufill; A Mummany; F Alonso; I Illa
Journal:  Neurology       Date:  2003-03-25       Impact factor: 9.910

2.  Myasthenia gravis in children: a longitudinal study.

Authors:  V V Ashraf; A B Taly; M Veerendrakumar; S Rao
Journal:  Acta Neurol Scand       Date:  2006-08       Impact factor: 3.209

3.  Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients.

Authors:  R Beekman; J B Kuks; H J Oosterhuis
Journal:  J Neurol       Date:  1997-02       Impact factor: 4.849

4.  Clinical and serological study of myasthenia gravis in HuBei Province, China.

Authors:  Xiaofan Zhang; Mingshan Yang; Jinzhi Xu; Min Zhang; Bethan Lang; Wei Wang; Angela Vincent
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-06       Impact factor: 10.154

5.  Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese.

Authors:  W H Chen; H C Chiu; R P Hseih
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

6.  Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000.

Authors:  Naoki Kawaguchi; Satoshi Kuwabara; Yuko Nemoto; Toshio Fukutake; Yoichi Satomura; Kimiyoshi Arimura; Mitsuhiro Osame; Takamichi Hattori
Journal:  J Neurol Sci       Date:  2004-09-15       Impact factor: 3.181

Review 7.  Clinical evaluation and management of myasthenia gravis.

Authors:  John C Keesey
Journal:  Muscle Nerve       Date:  2004-04       Impact factor: 3.217

Review 8.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

9.  Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians.

Authors:  H C Chiu; A Vincent; J Newsom-Davis; K H Hsieh; T Hung
Journal:  Neurology       Date:  1987-12       Impact factor: 9.910

10.  Repetitive nerve stimulation in myasthenia gravis--relative sensitivity of different muscles.

Authors:  João Costa; Teresinha Evangelista; Isabel Conceição; Mamede de Carvalho
Journal:  Clin Neurophysiol       Date:  2004-12       Impact factor: 3.708

View more
  6 in total

Review 1.  Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis.

Authors:  Kai Zhu; Jiaoxing Li; Xin Huang; Wei Xu; Weibin Liu; Jiaxin Chen; Pei Chen; Huiyu Feng
Journal:  Neurol Sci       Date:  2017-07-13       Impact factor: 3.307

2.  Long-term outcome of 424 childhood-onset myasthenia gravis patients.

Authors:  Mengcui Gui; Xuan Luo; Jing Lin; Yue Li; Min Zhang; Xiaofan Zhang; Mingshan Yang; Wei Wang; Bitao Bu
Journal:  J Neurol       Date:  2015-01-15       Impact factor: 4.849

3.  Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.

Authors:  Yu Hong; Geir Olve Skeie; Paraskevi Zisimopoulou; Katerina Karagiorgou; Socrates J Tzartos; Xiang Gao; Yao-Xian Yue; Fredrik Romi; Xu Zhang; Hai-Feng Li; Nils Erik Gilhus
Journal:  J Neurol       Date:  2017-03-31       Impact factor: 4.849

4.  A Randomized Control Study on the Efficacy of Thymectomy in Patients with Nonthymomatous (without Chest Tumor) Myasthenia Gravis.

Authors:  Ji Chen; Zhiming Chen; Feng Miao; Yang Song; Gang Chen; Yongjun Zhu; Liewen Pang; Jianying Xi; Chongbo Zhao; Xiaofeng Chen
Journal:  Ann Indian Acad Neurol       Date:  2020 Jan-Feb       Impact factor: 1.383

Review 5.  The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review.

Authors:  Jeannine M Heckmann; Tarin A Europa; Aayesha J Soni; Melissa Nel
Journal:  Front Neurol       Date:  2022-02-23       Impact factor: 4.003

6.  Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis.

Authors:  Dan He; Han Zhang; Jun Xiao; Xiaofan Zhang; Minjie Xie; Dengji Pan; Minghuan Wang; Xiang Luo; Bitao Bu; Min Zhang; Wei Wang
Journal:  Ann Neurol       Date:  2018-09       Impact factor: 10.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.